OncoSil Medical’s Device Outperforms SBRT in Pancreatic Cancer Treatment

An announcement from OncoSil Medical Ltd ( (AU:OSL) ) is now available.

OncoSil Medical Limited announced the results of a comparative analysis demonstrating the superiority of its OncoSil™ device over Stereotactic Body Radiation Therapy (SBRT) in treating locally advanced pancreatic cancer. The study showed that OncoSil™ significantly extends overall survival and progression-free survival compared to SBRT, with a higher rate of downstaging and surgical resection. These findings, presented at the Digestive Disease Week 2025, highlight the potential of OncoSil™ in treating earlier stages of pancreatic cancer and reinforce its efficacy and safety when added to standard chemotherapy. This development marks a significant milestone for OncoSil Medical, enhancing its positioning in the cancer treatment industry.

More about OncoSil Medical Ltd

OncoSil Medical Limited is a company specializing in cancer treatment devices, particularly the OncoSil™ brachytherapy device. This device is designed for the treatment of locally advanced unresectable pancreatic cancer, a condition with a typically poor prognosis due to late-stage diagnosis. The OncoSil™ device delivers targeted intratumoural placement of Phosphorous-32 in combination with chemotherapy and has received breakthrough device designation in the EU, UK, and US. It is approved for sale in over 30 countries, including the EU, UK, Türkiye, and Israel, with initial commercial treatments already conducted in Spain, Italy, and Israel.

Technical Sentiment Signal: Sell

Current Market Cap: A$16.12M

See more insights into OSL stock on TipRanks’ Stock Analysis page.